PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Respiratory Medicine, NHO Iwakuni Clinical Center, Iwakuni, Japan.\', \'Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.\', \'Center for Clinical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.\', \'Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Japan.\', \'Department of Medical Oncology, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Japan.\', \'Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan.\', \'General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.\', \'Department of Thoracic Oncology, NHO Shikoku Cancer Center, Matsuyama, Japan.\', \'Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1111/1759-7714.14281
?:doi
?:hasPublicationType
?:journal
  • Thoracic cancer
is ?:pmid of
?:pmid
?:pmid
  • 34964270
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.626
?:rankingScore_hIndex
  • 17
is ?:relation_isRelatedTo_publication of
?:title
  • Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all